Table 2: Compliance and tolerance to conventional dose TPF, N=28 patients.
|
Dose/cycle |
1st TPF |
2nd cycle Docetaxel |
2nd cycle Cisplatin |
2nd cycle 5 fluorouracil |
3rd cycle Docetaxel |
3rd cycle Cisplatin |
3rd cycle 5-fluorouracil |
|
100% |
28 (100%) |
22 (78.6%) |
22 (78.6%) |
22 (78.6%) |
21 (75%) |
20 (71.4%) |
20 (71.4%) |
|
80% |
0 |
6 (21.4%) |
6 (21.4%) |
6 (21.4%) |
5 (17.9%) |
6 (21.4%) |
5 (17.9%) |
|
0% |
0 |
0 |
0 |
0 |
2 (7.14%)* |
2 (7.14%)* |
2 (7.14%)* |
*One patient received 1st cycle chemotherapy (consisting of cisplatin and 5 fluorouracil) at another institution; another developed ST-elevation myocardial infarction.